Glaxo-Medicago Covid Shot Effective Against Delta in Trial
- Vaccine showed 71% efficacy against a range of variants
- Companies filing for authorization in U.S., U.K., Canada
View of vials on a production line at the factory of British multinational pharmaceutical company GlaxoSmithKline in Saint-Amand-les-Eaux, northern France.
Photographer: Francois Lo Presti/AFP/Getty Images
A Covid-19 vaccine from GlaxoSmithKline Plc and Canada’s Medicago Inc. demonstrated 71% efficacy against multiple variants of the disease in a positive outcome for the pandemic latecomers.
The companies also found the plant-based vaccine showed 75% efficacy against the highly-infectious delta variant and nearly 89% efficacy against the gamma variant first identified in Brazil, according to the advanced-stage trial results published Tuesday. No vaccinated participants developed severe disease and no serious side effects were reported in the study on about 24,000 people.